Skip to content

Optimization of acupuncture acupoint compatibility regimen for irritable bowel syndrome: a randomized controlled clinical trial

Optimization of acupuncture acupoint compatibility regimen for irritable bowel syndrome: a randomized controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078321
Enrollment
Unknown
Registered
2023-12-05
Start date
2023-12-18
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome with Predominant Diarrhea

Interventions

sensitive acupoints group:Pain thresholds were measured at 17 acupoints. Six acupoints (four bilateral acupoints and two single acupoints) with the highest sensitization degree were selected for acupu
sham acupuncture group:In this group, ten non-acupoints are chosen. The shallow needling method was used to penetrate the skin of the patient, and the needle tip was only penetrated 2-3mm under the sk

Sponsors

Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years (either sex); 2. Meets the diagnostic criteria of diarrheal-predominant irritable bowel syndrome (IBS-D); 3. Type 6 or 7 of the Bristol Stool Form Scale appeared for at least 4 days and type 1 or 2 appeared for less than 4 days in the last 2 weeks. The average score of daily abdominal pain was >= 3 in the last week; 4. No treatment of acupuncture in the last 6 months.

Exclusion criteria

Exclusion criteria: 1. Other sub -type IBS: IBS-C/ IBS-M/ IBS-U; 2. Participants with inflammatory bowel disease, microscopic colitis, celiac disease, Crohn's disease, and other organic bowel diseases (aged >= 50 years or have the following alarm signs that will be required to provide colonoscopy report within nearly 2 years: unexplained weight loss (weight loss > 10% within 3 months), hematochezia caused by non-hemorrhoids or anal fissure, nocturnal diarrhea, family history of colorectal cancer); 3. Use of antidepressant or IBS medication within 2 weeks before treatment, including traditional Chinese medicine (TCM) or proprietary Chinese medicine, antidiarrheal, antispasmodic, intestinal antibiotics, probiotics, and so on; 4. Diabetes mellitus ,abnormal thyroid function, severe acute or chronic organic diseases and kidney or liver diseases; 5. History of previous abdominal surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post-surgery is allowed); 6. Pregnancy or lactation; 7. History of alcohol and drug abuse; 8. Participate in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Effective response rate at week-6;

Secondary

MeasureTime frame
Effective response rate at other time points;Effective response rate of 50% of the 6-weeks treatment period;IBS symptom severity scale, IBS-SSS;Symptoms of abdominal pain;Symptoms of bloating;Days of loose stools;Patient Health Questionnaire-9, PHQ-9;Quality of life questionnaire, IBS-QOL;IBS Adequate Relief, IBS-AR;The Extraintestinal Symptom Scale;

Countries

China

Contacts

Public ContactCunzhi Liu

School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine

lcz_tg@126.com+86 10 5391 2201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026